Eli Lilly on Thursday posted better-than-expected quarterly results, but CVS Health's decision to drop the company's obesity ...

Despite its expensive valuation and declining estimates, we suggest investors hold LLY stock as the company boasts solid ...

A study of two blockbuster weight-loss drugs showed that users of Eli Lilly's Zepbound lost just over ... to our mission of empowering investor success. We provide a platform for our authors ...

Eli Lilly said its Zepbound obesity drug helped patients reduce ... freedom is essential to our mission of empowering investor success. We provide a platform for our authors to report on ...

Looking for undervalued stocks? Check out three top undervalued stocks to buy now in May, 2025 to boost your portfolio.

Eli Lilly’s expanding US production and advancing pipeline offset near-term headwinds and support bullish conviction. Read ...

Eli Lilly on Thursday posted better-than-expected first quarter revenue and profit, although sales of its popular weight-loss ...

Wall St. provides estimates for future stock prices of Eli Lilly from 2025 to 2030 based on projected revenue and net income.

We came across a bullish thesis on Eli Lilly and Company (LLY ... driven largely by the runaway success of its GLP-1-based treatments, Mounjaro and Zepbound. These two drugs alone are transforming ...

Eli Lilly launched a couple of new successful drugs, Mounjaro and Zepbound, that have boosted ... In 2021, Pfizer's COVID-19 vaccine success had many wondering how to invest in Pfizer.

Three Motley Fool contributors think they've found no-brainer healthcare stocks to buy in May. Here's why they picked Eli ...

Eli Lilly's stock dropped by 10.14% even though the company reported strong earnings for the first quarter. The ...